Clinical trials: Systemic Therapy
Advanced Hepatocellular Carcinoma, Lung Cancer
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical…
- Conditions
- Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
- Trial name
- NCT06644430
- Testing
- Ablation, system therapy
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Sun Yat-sen University
Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates
Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
This randomized controlled trial aims to evaluate the efficacy and safety of antibody-drug conjugate (ADC) plus immunotherapy compared with immunotherapy plus chemotherapy in patients with extensive transurethrally unresectable…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates, Immunotherapy, Chemotherapy
- Trial name
- NCT07879469
- Testing
- Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Tianjin Medical University Second Hospital
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center.
- Conditions
- Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
- Trial name
- PROMISE (NCT07696832)
- Testing
- Ivonescimab Injection
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Guangdong Association of Clinical Trials
Respiratory Tract Infections (RTI), Mucosal Immunity
Fermented Milk Drink With Lacticaseibacillus Paracasei Strain Shirota Helps Triathletes With Cold-Like Symptoms Before and After a Race
This study aims to evaluate whether a fermented milk drink containing the probiotic strain Lacticaseibacillus paracasei strain Shirota (LCS), commonly found in Yakult®, can help reduce upper respiratory symptoms in triathletes…
- Conditions
- Respiratory Tract Infections (RTI), Mucosal Immunity, Systemic Inflammation, Depressive Disorder
- Trial name
- NCT06970964
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC)
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at…
- Conditions
- OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
- Trial name
- NCT06841172
- Testing
- radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shandong Cancer Hospital and Institute
Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE
CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus
This study is evaluating the safety and potential benefits of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in children and young adults with severe systemic lupus erythematosus (SLE) that began during childhood.
- Conditions
- Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE, CD19 CAR-T Cell Therapy
- Trial name
- NCT07855302
- Testing
- SNUH-CD19-CAR-T Cells, Lymphodepleting Chemotherapy
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Seoul National University Hospital
SLE, Systemic Lupus Erythematosus (SLE)
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients…
- Conditions
- SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19
- Trial name
- NCT06839976
- Testing
- CART19
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital of Philadelphia
Brain Metastasis, Stereotactic Radiosurgery
OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
To remove a brain tumor, patients usually receive radiation to lower the chance that the cancer will come back in the spot where the tumor was removed.
- Conditions
- Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy
- Trial name
- NCT07655583
- Testing
- Systemic therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Therapy, Treatment
Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients
The aim of the current study is to evaluate the effect of melatonin administration on circulating levels of inflammatory mediators, oxidative stress, sleep quality, fatigue and quality of life in patients with SLE.
- Trial name
- SLE (NCT07721324)
- Testing
- Melatonin
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Ain Shams University
Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy
A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of Cadonilimab Injection in combination with Regorafenib in the treatment of intermediate to advanced hepatocellular carcinoma that has failed at least one prior systemic therapy .
- Trial name
- NCT05644379
- Testing
- Cadonilimab Injection, Regorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Systemic Lupus Erythematosus, CAR-T Cell Therapy
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
This is an investigator-initiated trial aimed at assessing the safety of anti-CD19 CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT06222853
- Testing
- anti-CD19-CAR-T cells
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.
- Trial name
- NCT06122389
- Testing
- SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Confirmed Diagnosis of Hepatocellular Carcinoma, Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery
Fibroscan Study in HCC
In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2.
- Conditions
- Confirmed Diagnosis of Hepatocellular Carcinoma, Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery, Child's A to C Cirrhosis
- Trial name
- NCT01796145
- Testing
- Fibroscan
- Where
- Hong Kong
- Volunteers
- 207 people
- Sponsor
- Chinese University of Hong Kong
Metastatic Gastric Cancer, Gastric Cancer
Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer
The results of the current studies to determine the optimal strategy for metastatic gastric cancer remain contrversial worldwide.
- Conditions
- Metastatic Gastric Cancer, Gastric Cancer, Systemic Therapy, Cytoreductive Gastrectomy
- Trial name
- CYGAS-GC (NCT06768463)
- Testing
- Cytoreductive Gastrectomy
- Where
- Vietnam
- Volunteers
- 250 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Advanced HCC, Systemic Therapy
Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
In China, primary hepatocellular carcinoma (HCC) has high morbidity and mortality, imposing a heavy burden on the public. Surgical resection is an effective treatment, but as HCC is often latent, less than 30% of patients are…
- Conditions
- Advanced HCC, Systemic Therapy, Chemotherapy, Immunotherapy
- Trial name
- T+I+XELOX (NCT06818097)
- Testing
- TKI, anti PD-1, XELOX chemotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
The purpose of this study is to evaluate the efficacy and safety of nanocrystalline medroxyprogesterone acetate for improving appetite and weight gain patients with non-small cell lung cancer (NSCLC) and cachexia and…
- Trial name
- NCT06961188
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, Standard Therapy
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone…
- Trial name
- NCT06961201
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
CAR T Cell Therapy, Systemic Lupus Erythematosus
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-BCMA/CD70 CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Conditions
- CAR T Cell Therapy, Systemic Lupus Erythematosus, BCMA
- Trial name
- NCT06934447
- Testing
- anti-BCMA/CD70-CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Systemic Lupus Erythematosus, Music Therapy
Adjunctive Yu-Tone Music Therapy for Systemic Lupus Erythematosus: a Prospective Cohort Study
The goal of this observational study is to investigate the long-term adjunctive effects of Traditional Chinese Five-Tone Therapy (Yu Tone) in patients with systemic lupus erythematosus (SLE).
- Trial name
- NCT06898489
- Testing
- Yu-Tone Music Intervention, Conventional pharmacotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Yijun Luo
Transarterial Chemoembolization, Systemic Therapy
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
The malignant degree of middle and advanced liver cancer is very high, and the survival prognosis of patients is very poor. TACE is currently the standard treatment for unresectable liver cancer recommended by several…
- Conditions
- Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT06788353
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University